Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
2024年1月7日 - 10:00PM
Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology
Company®, in collaboration with Enable Medicine, a leading provider
of AI-powered biological insights, announces the availability of
MaxFuse, an advanced algorithm co-developed in the laboratory of
Dr. Garry Nolan for integrating multiomic single-cell and spatial
datasets*. Dr. Nolan is a co-founder and member of the Board of
Directors of Akoya Biosciences.
Recent technology advancements have enabled analyses of the
proteome, metabolome, transcriptome, and epigenome both spatially
and at the single-cell level. However, the ability to integrate the
data from these diverse modalities and platforms is challenging.
The MaxFuse algorithm from Dr. Nolan was developed to overcome
these limitations and provides a reliable, fast, cost-effective,
and scientifically powerful means to integrate spatial proteomic
data with single-cell transcriptomic and epigenomic data sets.
The development, co-developers, and applications of MaxFuse were
described in recent Nature and Nature Biotechnology
publications:
- Integration of
spatial and single-cell data across modalities with weakly linked
features
- Organization of the
human intestine at single-cell resolution
“MaxFuse was developed to address the challenge and opportunity
to deliver an algorithmic solution to link multimodal and multiomic
datasets,” said Garry Nolan, whose laboratory co-developed MaxFuse.
“MaxFuse represents a significant advancement in the analytics
capabilities needed to maximize the value of data derived from
spatial and single-cell technologies. The relationships that can be
revealed by AI and reinforced learning when incorporated into tools
such as MaxFuse can enable scientists to maximize the value of both
new and historical data sets, contributing to the acceleration of
the pace of discoveries derived from these technologies.”
Akoya’s customers can access MaxFuse through the Enable Medicine
AI-Cloud Platform.
“Our partnership with Akoya and Dr. Nolan continues to advance
in generating new and exciting tools for spatial biology analysis,”
said Aaron Mayer, co-founder and Chief Scientific Officer of Enable
Medicine. “MaxFuse will help generate powerful data by connecting
diverse data-generating modalities, supporting the acceleration of
discoveries and the progress towards clinical application.”
A two-part webinar series featuring Garry Nolan and Aaron Mayer
entitled "AI-Powered Tissue Atlas: Fusing Single-cell Genomics and
Spatial Proteomics with MaxFuse" will be hosted by Genetic
Engineering & Biotechnology News (GEN) on February 26th and
March 8th, 2024.
* MaxFuse was developed in collaboration with the laboratories
of Nancy Zhang and Zongming Ma at the University of
Pennsylvania.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
expectations about the potential of our products and services and
other matters regarding our business strategies and plans and
objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
To learn more about Akoya, visit www.akoyabio.com.
About Enable Medicine
At Enable Medicine, our mission is to organize the world's
biological data and make it searchable to generate profound new
insights into health and disease. We are building the largest and
most comprehensive atlas of human biology to index, interconnect
and interrogate diverse data inputs from billions of cells and
across thousands of patient data sets. On the Enable biological
insight, operating and search (BIOS) platform, scientists use the
computational power of generative AI to search these atlases and
unlock answers to previously unanswerable questions. Together, we
empower those bringing the next generation of diagnostics and
therapeutics forward to deliver better patient outcomes. To
accelerate your discoveries with AI-powered biological search on
the Enable Medicine Platform, visit
http://www.enablemedicine.com.
Akoya Biosciences Investor Contact
Priyam Shahinvestors@akoyabio.com
Akoya Biosciences Media Contact:
Christine Quernmedia@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
過去 株価チャート
から 4 2024 まで 5 2024
Akoya BioSciences (NASDAQ:AKYA)
過去 株価チャート
から 5 2023 まで 5 2024